Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Krystal Biotech holds a consensus rating of "Moderate Buy" from 10 analysts (8 buy, 2 hold) with an average 1‑year price target of $326.25, and several firms recently raised targets (e.g., Goldman Sachs to $327, Citi to $371).
• The company beat estimates last quarter with EPS of $1.70 versus $1.62 expected and revenue of $107.11M versus $105.30M, while the stock trades with a market cap of $7.35B and a P/E of 36.7.
• Insiders have sold 129,164 shares in the past 90 days worth about $34.54M (including a 25,000‑share sale by Suma Krishnan for $6.58M), though insiders still own roughly 13.70% of the company.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $326.25.

A number of equities research analysts have issued reports on the stock. The Goldman Sachs Group increased their price objective on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a "buy" rating in a report on Friday, January 30th. HC Wainwright reissued a "buy" rating and issued a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Weiss Ratings lowered shares of Krystal Biotech from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday. Guggenheim lifted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Finally, Citigroup boosted their price target on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $263.21, for a total value of $6,580,250.00. Following the sale, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the transaction, the chief accounting officer directly owned 22,366 shares of the company's stock, valued at approximately $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 129,164 shares of company stock valued at $34,538,578. 13.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Seven Fleet Capital Management LP bought a new position in shares of Krystal Biotech during the 4th quarter valued at approximately $986,000. Pacer Advisors Inc. increased its position in Krystal Biotech by 182.0% in the fourth quarter. Pacer Advisors Inc. now owns 1,712 shares of the company's stock worth $422,000 after purchasing an additional 1,105 shares during the last quarter. Vident Advisory LLC raised its stake in Krystal Biotech by 5.4% during the fourth quarter. Vident Advisory LLC now owns 1,494 shares of the company's stock valued at $368,000 after purchasing an additional 76 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in Krystal Biotech during the fourth quarter valued at $455,000. Finally, Empowered Funds LLC bought a new position in Krystal Biotech during the fourth quarter valued at $212,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Down 1.4%

NASDAQ KRYS opened at $251.40 on Friday. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 36.70 and a beta of 0.49. The business has a 50-day moving average price of $268.13 and a 200-day moving average price of $228.50. Krystal Biotech has a twelve month low of $122.80 and a twelve month high of $298.30.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million for the quarter, compared to the consensus estimate of $105.30 million. Research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.